NYSE:IMVIMV Stock Price, Forecast & News

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMV shares have increased by 24.4% and is now trading at $2.96. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV.

IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV.

Imv Inc (NYSE:IMV) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.04 million. View IMV's earnings history.

7 brokers have issued 1-year price objectives for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's stock price to reach $7.42 in the next year. This suggests a possible upside of 150.6% from the stock's current price. View analysts' price targets for IMV.

Press coverage about IMV stock has been trending negative on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IMV earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about IMV.

Some companies that are related to IMV include Aptose Biosciences (APS), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), Emblem (EMC) and Medicenna Therapeutics (MDNA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY).

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMV stock can currently be purchased for approximately $2.96.

IMV has a market capitalization of $181.23 million.

The company can be reached via phone at (902) 492-1819.